Abstract Juvenile idiopathic arthritis (JIA) is the most common inflammatory rheumatic disease with onset in childhood. Many children and young people with JIA continue to be affected by the condition as adults and require ongoing management. The objective of this guideline is to provide up-to-date, evidence-based recommendations for the holistic management of children and young people (CYP), and adults with JIA. It will incorporate the use of imaging for diagnosis and monitoring of disease activity and damage, alongside non-pharmacological and pharmacological management including glucocorticoid intra-articular injections where indicated, as well as screening for co-morbidities, access to developmentally appropriate care, and a structured transition between paediatric and adult rheumatology services. We will cover the role of quality improvement methodologies and cutting-edge clinical research in advancing the delivery of care to people with JIA, and the importance of bridging health inequalities to improve outcomes. This guideline will exclude the pre-treatment screening, monitoring and safety of conventional synthetic, biologic and targeted synthetic disease-modifying anti-rheumatic drugs which are covered in other guidelines. This guideline will provide recommendations applicable across all four nations of the UK as well as being of relevance internationally.
Compeyrot-Lacassagne et al. (Tue,) studied this question.